Synopsis: Anlon Healthcare Limited approved a 1:5 stock split and a 1:1 bonus issue, aiming to improve share affordability, increase liquidity, and encourage broader investor participation.
This Micro-cap Pharma Stock, engaged in manufacturing high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for medicines, nutraceuticals, and healthcare products, jumped 5.94 percent after the company’s board of directors ro approved a 1:5 stock split and a 1:1 bonus issue.
With a market capitalization of Rs. 620.54 crores, the share of Anlon Healthcare Limited has reached an intraday high of Rs. 118.55 per equity share, rising nearly 5.94 percent from its previous day’s close price of Rs. 111.90. Since then, the stock has retreated and is currently trading at Rs. 116.75 per equity share.
Reason Behind the Surge:
Anlon Healthcare Limited’s Board of Directors, in its March 06, 2025, board meeting, approved a 1:5 stock split, aiming to make shares more affordable and improve market participation.
The board had decided to issue a stock split at a ratio of 1:5, meaning that each equity share’s face value of Rs. 10 will be divided into five equity shares with a share value of Rs. 2 each.
For example, if a shareholder owns 1,000 shares valued at Rs. 10 each in Anlon Healthcare Limited, after the 1:5 stock split, their total holding will increase to 5,000 shares with a face value of Rs. 2 each. The value of the holding will remain unchanged.
Additionally, the company’s Board of Directors has also decided to issue bonus shares at a ratio of 1:1, meaning that shareholders will receive one new fully paid-up equity share of Rs. 2 each for every one existing fully paid-up equity share they hold.
For example, if a shareholder owns 5,000 shares of Anlon Healthcare Limited, they will receive 5,000 bonus shares, bringing their total holding to 10,000 shares after the 1:1 bonus issue.
Future Outlook:
Anlon Healthcare Limited is focusing on expanding its product portfolio and strengthening operations to support long-term growth. The company plans to launch 7 new APIs in FY2026-27, entering additional therapeutic categories and expanding its addressable market. With improved product mix and operating leverage, it expects to achieve EBITDA margins of around 25-30 percent in the medium term.
The company is also diversifying its business by entering industrial and fine chemicals, which could create new revenue streams and reduce reliance on pharmaceutical products. Along with acquisitions and new product launches, management aims to deliver around 30 percent revenue CAGR over the next three years.
To support expansion, the company plans $3–5 million in capital expenditure during FY2026–27. After expansion, installed capacity is expected to increase to about 1,400–1,600 MTPA, while a stronger R&D pipeline will help drive future growth.
Business Highlights:
Anlon Healthcare Limited has built a strong global presence with operations across 15 countries. The company has filed 21 Drug Master Files with global regulatory authorities, showing its focus on compliance and quality standards. It also serves a wide customer base of around 125 clients worldwide, including both direct and indirect customers.
The company has a diverse product portfolio with 65 commercialized products, 28 products currently in the pilot stage, and 49 products under laboratory testing. Anlon Healthcare also has a manufacturing capacity of about 400 MTPA, which supports its production and growth plans in the pharmaceutical and healthcare sector.
Company Overview:
Anlon Healthcare Limited was incorporated in 2013 and is an Indian pharmaceutical company involved in manufacturing and distributing pharma intermediates and active pharmaceutical ingredients (APIs), supplying them to formulators in India and overseas. It operates as a research-driven, compliance-focused player serving medicines, nutraceuticals, personal care, and veterinary product makers.
Revenue Mix (FY25):
In FY25, Anlon Healthcare Limited generated most of its revenue from APIs, contributing 58.13 percent of total revenue. Pharmaceutical intermediates accounted for 35.70 percent, while nutraceuticals contributed 6.16 percent, reflecting the company’s focus on API manufacturing.
Recent Quarter Results:
Coming into financial highlights, Anlon Healthcare Limited’s revenue has increased from Rs. 9.36 crore in Q3 FY25 to Rs. 35.58 crore in Q3 FY26, which has grown by 280.13 percent. The net profit of the company has converted from negative to positive, from a net loss of Rs. 2.49 crore in Q3 FY25 to a net profit of Rs. 5.15 crore in Q3 FY26. Anlon Healthcare Limited’s revenue has grown at a CAGR of 65.49 percent over the last four years.
In terms of return ratios, the company’s ROCE and ROE stand at 24.8 percent and 40.4 percent, respectively. Anlon Healthcare Limited has an earnings per share (EPS) of Rs. 0.27, and its debt-to-equity ratio is 5.15x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 1:1 Bonus and 1:5 Stock Split: Pharma stock jumps 6% after board approves bonus issue and share split appeared first on Trade Brains.